Asia Pacific Pharmaceutical Contract Manufacturing Organization Market Outlook 2031
The Asia Pacific pharmaceutical contract manufacturing organization market size was USD 46.66 Billion in 2022 and is anticipated to reach USD 98.86 Billion by 2031 expand at a significant CAGR 8.7% during the forecast period, 2023–2031. Growth of the market is attributed to rising healthcare expenditure, increasing demand for cost control in drug development, and increasing investments in pharmaceutical research and development.
Contract manufacturing organization is a corporation that assists other companies in the pharmaceutical sector on a contract basis to provide broad services from drug manufacturing through drug development. This permits major pharmaceutical players to overcome those phases of the business.
The Covid-19 pandemic affected the demand and supply of pharmaceutical contract manufacturing organization market. Lockdown across the globe, supply chain disorders, and oscillating supply of raw materials forced manufacturers to shut down production leading to unfortunate decline in market growth. Launch of vaccines to combat the Covid-19 pandemic is expected to contribute to the market growth over the forecast period.
Asia Pacific Pharmaceutical Contract Manufacturing Organization Market Trends, Drivers, Restraints, and Opportunities
- Increasing access to advanced technologies is projected to boost the market.
- Increasing demand for biological therapies is the major factor fueling the market.
- Lack of manufacturing standardization is projected to restrict the market growth during the forecast period.
- High price of services is anticipated to hamper the market growth in the coming years.
- R&D investment and technological advancement in pharmaceutical contract manufacturing organization market is projected to offer lucrative opportunities for the market players.
Scope of The Asia Pacific Pharmaceutical Contract Manufacturing Organization Market Report
The report on the Asia Pacific pharmaceutical contract manufacturing organization market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Pharmaceutical Contract Manufacturing Organization Market – Asia Pacific Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2016-2021
|
|
Forecast Period
|
2023-2031
|
|
Segmentation
|
Service Types [Finished Dosage Formulation Development and Manufacturing (Injectable Dose Formulation, Solid Dose Formulation, and Liquid Dose Formulation), Secondary Packaging, and Active Pharmaceutical Ingredient Manufacturing(High Potency API[HPAPI], Small Molecules, and Large Molecules)], End - Users [Healthcare Providers and Healthcare Payers]
|
|
Geographical Scope
|
Australia, India, China, Japan, and Rest of Asia Pacific
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players covered in the Report
|
Lonza Group, Famer SA, Pfizer Centre Source [Pfizer Inc], Boehringer Ingelheim Group, Jubilant Life Sciences Ltd, Recipharm AB, Aenova Group, Baxter Biopharma Solutions, Thermo Fisher Scientific Inc.[Patheon Inc.], and Catalent Inc.
|
Asia Pacific Pharmaceutical Contract Manufacturing Organization Market Segment Insights
The finished dosage formulation development and manufacturing accounts for a key share of the market
Based on service types, the Asia Pacific pharmaceutical contract manufacturing organization market is segregated into finished dosage formulation development & manufacturing, secondary packaging, & active pharmaceutical ingredient manufacturing. The finished dosage formulation development and manufacturing segment is sub-segmented into injectable dose formulation, solid dose formulation, and liquid dose formulation.
The active pharmaceutical ingredient manufacturing segment is sub-segmented into high potency API[HPAPI], small molecules, and large molecules. The finished dosage formulation development and manufacturing segment accounts for a key share of the market. Growth of the market is attributed to growing focus on specialty medicines and rapid growth in the nuclear medicines sector.
However, the active pharmaceutical ingredient manufacturing segment is anticipated to expand at a rapid pace during the forecast period due to factors such as advancement in cell and gene therapies, growing number of cell therapy candidates, and rapid progression through the various phases.
The healthcare providers segment accounts for a key share of the market
Based on end-users, the Asia Pacific pharmaceutical contract manufacturing organization market is divided into healthcare providers and healthcare payers. The healthcare providers segment accounts for a key share of the market. Growth of the market is attributed to increasing demand for facilities that offer manufacturing services, high demand for end-to-end services in pharmaceutical and growing demand for biosimilars & vaccines.
However, the healthcare payers segment is anticipated to expand at a rapid pace during the forecast period due to factors such as growing need to streamline execution costs, increasing number of clinical trials, and presence of leading pharmaceutical companies.
The market in Japan is anticipated to hold a major market share
On the basis of region, the Asia Pacific pharmaceutical contract manufacturing organization market is classified as Australia, India, China, Japan, and Rest of Asia Pacific. The market in India is estimated to expand at a high CAGR during the forecast period due to growing demand for generic medicines, growth in the medicinal areas, and innovation of new drugs to fight against high-potency diseases.
The market of Japan is estimated to hold a major market share due to regulatory approval of the drug, increasing demand for next-generation biological therapies, and increasing government initiatives in healthcare sector.
Segments
The Asia Pacific pharmaceutical contract manufacturing organization market has been segmented on the basis of
Service Types
- Development and Manufacturing
- Injectable Dose Formulation
- Solid Dose Formulation
- Liquid Dose Formulation
- Secondary Packaging
- Active Pharmaceutical Ingredient Manufacturing
- High Potency API[HPAPI]
- Small Molecules
- Large Molecules
End-Users
- Healthcare Providers
- Healthcare Payers
Region
Key Players
- Lonza Group
- Famer SA
- Pfizer Centre Source [Pfizer Inc]
- Boehringer Ingelheim Group
- Jubilant Life Sciences Ltd
- Recipharm AB
- Aenova Group
- Baxter Biopharma Solutions
- Thermo Fisher Scientific Inc.[Patheon Inc.]
- Catalent Inc.
Competitive Landscape
Key players competing in the Asia Pacific pharmaceutical contract manufacturing organization market include Lonza Group, Famer SA, Pfizer Centre Source [Pfizer Inc], Boehringer Ingelheim Group, Jubilant Life Sciences Ltd, Recipharm AB, Aenova Group, Baxter Biopharma Solutions, Thermo Fisher Scientific Inc.[Patheon Inc.], and Catalent Inc.
Some of these players are using several market strategies such as acquisitions, merger, collaborations, partnerships, capacity expansion, and product launches to enhance their market shares and to generate revenue and rise their production line of the business in the coming years.
Request For Customization
Enquiry Before Buying
Speak With Analyst
